Biotech companies continue to strike while the capital markets are hot, with an IPO from San Diego’s Celladon Corp. expected to debut this week.
A Cooley team led by partner Jason Kent is advising the clinical-stage cardiovascular company. Latham & Watkins, led by partner Cheston Larson, is working with underwriters J.P. Morgan and Barclays. A filing with the U.S. Securities and Exchange Commission disclosed that Cooley owns less than 1 percent of the company’s outstanding stock.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
